sitagliptin + acarbose

Sitagliptin + acarbose is an oral combination therapy for type 2 diabetes mellitus, consisting of two small molecule agents with complementary mechanisms. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels, leading to glucose-dependent stimulation of insulin secretion and suppression of glucagon release. Acarbose is an alpha-glucosidase inhibitor that delays carbohydrate absorption in the intestine, thereby reducing postprandial blood glucose spikes. The combination has been studied for its additive effects on glycemic control and incretin hormone modulation, particularly in patients with predominant postprandial hyperglycemia[1][3]. While both drugs are approved individually for type 2 diabetes, this specific combination does not have a unique fixed-dose brand name or widespread regulatory approval as a co-formulated product.